Article Details

Lyell Immunopharma to be valued at up to $4.4 billion after IPO terms set

Retrieved on: 2021-06-09 12:10:06

Tags for this article:

Click the tags to see associated articles and topics

Lyell Immunopharma to be valued at up to $4.4 billion after IPO terms set. View article details on hiswai:

Excerpt

Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley are the lead underwriters. Lyell reported a net loss of $204.5 million on revenue of ...

Article found on: www.marketwatch.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up